Intratumour injection of immunoglobulins labelled with the a-particle emitter 21'At: analyses of tumour retention, microdistribution and growth delay
1998

Using Astatine-211 to Treat Tumors with Antibodies

Sample size: 24 publication Evidence: moderate

Author Information

Author(s): RH Larsen, OS Bruland

Primary Institution: University of Oslo; Duke University Medical Center; The Norwegian Radium Hospital

Hypothesis

Can intratumour injections of 211At-labelled antibodies effectively target and treat solid tumors?

Conclusion

The study found that intratumour injections of 211At-labelled antibodies can significantly delay tumor growth.

Supporting Evidence

  • The retention of the specific antibody was significantly higher than the non-specific antibody.
  • The tumor growth was significantly delayed as a function of the injected activity dosage.
  • Approximately 50% of the injected activity left the tumors within 0.5 hours after injection.

Takeaway

This study shows that injecting a special type of medicine directly into tumors can help slow down their growth.

Methodology

Nude mice with human osteosarcoma xenografts received intratumour injections of 211At-labelled antibodies, and tumor retention and growth were measured.

Limitations

The study observed heterogeneous radiation dose distribution within the tumors.

Participant Demographics

Nude mice carrying OHS human osteosarcoma xenografts.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication